Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits

scientific article published on 01 July 1995

Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1254/FPJ.106.41
P953full work available at URLhttps://www.jstage.jst.go.jp/article/fpj1944/106/1/106_1_41/_pdf
P698PubMed publication ID7590522

P2093author name stringT. Mori
H. Kasai
T. Nagayama
K. Saitoh
A. Tsuchiya
S. Ohbayashi
P433issue1
P407language of work or nameJapaneseQ5287
P304page(s)41-50
P577publication date1995-07-01
P1433published inFolia Pharmacologica JaponicaQ15764489
P478volume106

Reverse relations

cites work (P2860)
Q446124582‐Cyclopenten‐1‐one and prostaglandin J2 reduce restenosis after balloon angioplasty in rats: role of NF‐κB
Q47877643Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
Q33993678Current, new and future treatments in dyslipidaemia and atherosclerosis
Q30476274PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
Q28289022Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future
Q47726428Regulation of apo A-I gene expression by fibrates
Q35027759Regulation of chemokine expression in atherosclerosis
Q35541858Role of Monocytes in Atherogenesis
Q34047291Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis

Search more.